Breaking News

Argentina Dollar Bonds Due 2033 Drop for Second Day
Tweet TWEET

Statement From Sarepta Therapeutics on Stock Volatility

Statement From Sarepta Therapeutics on Stock Volatility 
CAMBRIDGE, MA -- (Marketwire) -- 01/30/13 --   Sarepta Therapeutics
(NASDAQ: SRPT), a developer of innovative RNA-based therapeutics,
today issued the following statement from Chris Garabedian, President
and Chief Executive Officer, to address volatility in the Company's
stock price resulting from anonymous comments on a social media site
that were later deleted. 
"As a growing company, we may be subject to market rumors through
social media and other anonymous sources. While we do not comment on
such rumors, we believe it is important to remind our shareholders
that Sarepta communicates material information in accordance with our
obligations as a public company. In addition, in circumstances where
false or misleading information is communicated that negatively
impacts the company, we will take appropriate action. As we have
previously stated, we look forward to meeting with the FDA this
quarter for an end of Phase 2 clinical meeting to address the path
forward for eteplirsen, our investigational treatment for Duchenne
muscular dystrophy." 
About Sarepta Therapeutics 
Sarepta Therapeutics is focused on developing first-in-class
RNA-based therapeutics to improve and save the lives of people
affected by serious and life-threatening rare and infectious
diseases. The Company's diverse pipeline includes its lead program
eteplirsen, for Duchenne muscular dystrophy, as well as potential
treatments for some of the world's most lethal infectious diseases.
Sarepta aims to build a leading, independent biotech company
dedicated to translating its RNA-based science into transformational
therapeutics for patients who face significant unmet medical needs.
For more information, please visit us at www.sareptatherapeutics.com. 
Forward-Looking Statements and Information 
In order to provide Sarepta's investors with an understanding of its
current results and future prospects, this press release contains
statements that are forward-looking. Any statements contained in this
press release that are not statements of historical fact may be
deemed to be forward-looking statements. Words such as "believes,"
"anticipates," "plans," "expects," "will," "intends," "potential,"
"possible" and similar expressions are intended to identify
forward-looking statements. These forward-looking statements include
statements about the development of eteplirsen and its efficacy,
potency and utility in the treatment of DMD. 
These forward-looking statements involve risks and uncertainties,
many of which are beyond Sarepta's control. Known risk factors
include, among others: clinical trials may not demonstrate the safety
and efficacy of eteplirsen and/or Sarepta's antisense-based
technology platform; treatment of patients with DMD using eteplirsen
over a longer duration may not lead to significant clinical benefit;
and any of Sarepta's drug candidates, including eteplirsen, may fail
in development, may not receive required regulatory approvals, or be
delayed to a point where they do not become commercially viable. 
Any of the foregoing risks could materially and adversely affect
Sarepta's business, results of operations and the trading price of
Sarepta's common stock. For a detailed description of risks and
uncertainties Sarepta faces, you are encouraged to review the
Company's filings with the Securities and Exchange. 
Sarepta Investor Contact: 
Erin Cox
425.354.5140 
ecox@sareptatherapeutics.com  
Sarepta Media Contact:
Jim Baker
617.444.8424 ext. 3124
jbaker@sareptatherapeutics.com